Functionally, the combination of an LSD1 inhibitor and an anti-PD-1 mAb could overcome tumor immune evasion and greatly inhibit tumor growth, which was associated with reduced Ki-67 levels and augmented CD8+ T cell infiltration in immunocompetent tumor-bearing mouse models. Here, CD8A is linked to neoplasm.